Genomics in Cancer Care Market to Reach USD 72.87 Billion by 2033 | Strong 16.8% CAGR | North America Leads with 38% Share | Key Players: Illumina, Thermo Fisher Scientific, BGI Genomics, QIAGEN, Roche, Guardant Health, Natera

Genomics in Cancer Care Market Overview

The global genomics in cancer care market reached US$ 16.14 billion in 2023, with an estimated rise to US$ 18.6 billion in 2024, and is projected to reach US$ 72.87 billion by 2033, growing at a CAGR of 16.8% during the forecast period 2025-2033. The market is being driven by the increasing adoption of genomic technologies for early cancer detection, personalized treatment, and disease monitoring. Genomics enables healthcare providers to tailor therapies based on individual genetic profiles, improving treatment efficacy and patient outcomes.

A major factor fueling market growth is the integration of liquid biopsy technologies, which allow non-invasive analysis of circulating tumor DNA (ctDNA) or other biomarkers from a simple blood sample. Liquid biopsies provide a cost-effective, rapid, and minimally invasive alternative to traditional tissue biopsies, enabling early cancer detection, continuous disease monitoring, and evaluation of treatment responses. Companies such as Guardant Health and Foundation Medicine are pioneering these platforms, supporting the shift toward precision oncology and improved clinical decision-making.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/genomics-in-cancer-care-market?Juli

Recent Developments:

✅ October 2025: Guardant Health launched an enhanced liquid biopsy panel with expanded genomic coverage for early detection and minimal residual disease (MRD) monitoring across multiple cancer types, improving sensitivity and clinical utility.

✅ September 2025: Foundation Medicine introduced a new AI‐augmented genomic profiling platform that integrates whole‐exome sequencing with advanced tumor mutational burden analysis to support precision oncology decision‐making.

✅ June 2025: A leading global diagnostics consortium announced rollout of next‐generation sequencing (NGS) fusion assays for solid tumors, enabling faster and more accurate detection of actionable genomic alterations in clinical practice.

✅ April 2025: Illumina expanded its oncology portfolio with a high‐throughput sequencing solution designed for integrated cancer genomics workflows, enabling laboratories to increase throughput and reduce turnaround times.

✅ March 2025: Several major cancer centers in North America and Europe adopted multi‐omics platforms that combine genomics, transcriptomics, and proteomics to deliver deeper insights into tumor biology and personalized therapy selection.

✅2024-2025: Increased collaboration between pharmaceutical companies and genomic diagnostics firms accelerated development of companion diagnostics tied to targeted therapies, enabling more precise patient stratification in clinical trials and routine oncology care.

✅In September 2025, The Hyundai Motor India Foundation (HMIF) and IIT Madras have launched 'Hyundai Hope for Cancer', a program aimed at improving pediatric cancer care in India. The initiative includes the Hyundai Center for Cancer Genomics at IIT Madras, Chennai.

Mergers & Acquisitions:

✅ Abbott's acquisition of Exact Sciences: In November 2025, Abbott announced plans to acquire cancer test maker Exact Sciences in a deal valued at approximately US$ 21 billion, expanding Abbott's presence in cancer screening and genomic diagnostics, including markers such as Oncotype DX and liquid biopsy tests. This acquisition marks a major strategic entry by Abbott into oncology diagnostics and cancer genomics.

✅ Illumina and Grail divestiture: Following regulatory scrutiny, Illumina agreed to unwind its prior acquisition of cancer‐screening company Grail, created to accelerate early multi‐cancer detection through blood‐based genomics assays. This divestiture reflects ongoing antitrust challenges and reshapes competitive dynamics in the cancer genomics testing market.

✅ GeneDx acquisition of Fabric Genomics: In 2025, GeneDx completed a US$ 51 million acquisition of AI‐driven genomic interpretation specialist Fabric Genomics, enhancing its genomic testing services and analytics capabilities for clinical cancer care and hereditary risk profiling.

✅ Truveta investment consortium: In January 2025, genomic research and data platform Truveta secured a US$ 320 million strategic investment from partners including Regeneron Pharmaceuticals and Illumina to build one of the largest genetic databases. Although not an outright acquisition, this partnership significantly strengthens genomic data resources crucial for cancer care and precision oncology.

✅ Thermo Fisher and broader precision medicine M&A: Historical and ongoing M&A by companies such as Thermo Fisher Scientific to expand their molecular diagnostics and personalized medicine portfolios highlights the consolidation trend in technologies underlying the genomics in cancer care market.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=genomics-in-cancer-care-market?Juli

Key Players:

• Illumina - Holds a 22% share of the market, driven by its advanced next-generation sequencing (NGS) platforms that support precision oncology, liquid biopsy, and genomic research applications.

• Thermo Fisher Scientific - Accounts for 17% of the market, fueled by its comprehensive genomic solutions, including PCR assays, NGS platforms, and bioinformatics tools for early cancer detection and personalized treatment.

• BGI Genomics - Holds a 12% share, supported by its genomic sequencing services, biomarker discovery, and population-scale cancer genomics research capabilities.

• QIAGEN - Holds 10% of the market, driven by molecular diagnostics, liquid biopsy kits, and sample preparation solutions that facilitate cancer detection and monitoring.

• Roche - Accounts for 14%, combining diagnostics and therapeutics in oncology, including companion diagnostics and targeted genomics solutions.

• Guardant Health - Holds 13% of the market, with focus on ctDNA-based liquid biopsies for non-invasive cancer detection, monitoring, and treatment planning.

• Natera - Represents 12%, specializing in cell-free DNA testing for oncology and genetic risk assessment, enabling personalized cancer care strategies.

Market Segmentation:

➥ By Product Type, Instruments dominate the market with a 55% share, driven by the growing adoption of advanced sequencing platforms, PCR machines, and microarray systems for cancer diagnostics, personalized therapy, and research applications. Consumables hold a 45% share, including reagents, kits, and sample preparation materials that are essential for NGS, PCR assays, and liquid biopsy workflows.

➥ By Technology, Next-Generation Sequencing (NGS) leads with a 40% share, fueled by its high-throughput, comprehensive genomic profiling capabilities for early cancer detection, mutation analysis, and treatment planning. PCR accounts for 25%, widely used for targeted mutation detection, gene expression analysis, and companion diagnostics. Microarrays hold 15%, applied in biomarker discovery and gene expression studies, while Nucleic Acid Extraction & Purification contributes 10%, providing critical sample processing solutions. Others technologies, including emerging platforms such as CRISPR-based assays and proteogenomics, hold 10% of the market.

➥ By Application, Diagnostics dominates with a 50% share, driven by the need for early cancer detection, risk assessment, and monitoring of treatment response. Personalized Medicine accounts for 30%, supported by genomic-guided therapy selection and precision oncology initiatives. Drug Discovery & Development contributes 20%, leveraging genomic profiling for biomarker discovery, preclinical research, and clinical trial design.

➥ By End-User, Hospitals & Oncology Clinics lead with a 35% share, utilizing genomic technologies for patient diagnostics and personalized treatment planning. Diagnostic Labs hold 30%, offering centralized genomic testing services. Academic & Research Centers account for 20%, driving innovation in cancer genomics and translational research. Pharma & CROs represent 15%, employing genomics for drug development, clinical trial stratification, and biomarker discovery.

Regional Insights:

North America dominates the genomics in cancer care market with a 38% share, driven by the presence of leading genomics companies, high healthcare expenditure, well-established oncology infrastructure, and favorable reimbursement policies. The U.S. is a key contributor, with widespread adoption of NGS, liquid biopsy technologies, and precision oncology initiatives enhancing early detection and personalized treatment.

Europe holds a 28% share, supported by advanced healthcare systems, strong government funding for cancer research, and growing awareness of genomics-based diagnostics. Countries such as Germany, the U.K., and France are investing in genomic medicine programs and expanding access to precision oncology solutions.

Asia-Pacific accounts for 22% of the market, experiencing rapid growth due to rising cancer prevalence, improving healthcare infrastructure, increasing investments in genomics research, and growing adoption of NGS and PCR technologies in countries like China, Japan, and India. Expanding awareness of precision medicine and government-led healthcare initiatives are accelerating market penetration in this region.

Latin America contributes 7%, driven by emerging healthcare infrastructure, increasing awareness of advanced diagnostics, and gradual adoption of genomic technologies in oncology centers.

Middle East & Africa represents 5% of the market, with growth supported by investments in healthcare modernization, rising cancer incidence, and adoption of molecular diagnostic technologies in key countries like Saudi Arabia, UAE, and South Africa.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/genomics-in-cancer-care-market?Juli

Market Dynamics:

Drivers:
Rising adoption of next-generation sequencing (NGS) in oncology diagnostics is significantly driving the genomics in cancer care market growth. NGS allows comprehensive profiling of hundreds to thousands of genes simultaneously, detecting single nucleotide variants, insertions, deletions, copy number alterations, and gene fusions in a single test. This enables oncologists to identify actionable mutations and design targeted treatment strategies, significantly improving patient outcomes. For instance, in July 2025, Illumina Inc. unveiled the TruSight Oncology 500 v2 assay, delivering comprehensive genomic profiling to support therapy selection and clinical trial matching, with an enhanced sample-to-analysis workflow for research laboratories.

Restraints:
Limited reimbursement policies and regulatory challenges are hampering market growth. Despite advancements, genomic tests such as NGS and comprehensive genomic profiling remain expensive, and standardized reimbursement frameworks are lacking, particularly in emerging markets. While the U.S. Centers for Medicare & Medicaid Services provides coverage for some FDA-approved NGS-based diagnostics, similar support is inconsistent in Europe and Asia-Pacific. Regulatory complexities further hinder innovation and commercialization, restraining the market's growth potential.

Opportunities:
The increasing emphasis on precision medicine and personalized oncology treatments presents significant opportunities. Rising investments in genomic research, growing collaborations between biotech companies and healthcare institutions, and expanding applications of liquid biopsy technologies for early detection and disease monitoring are expected to fuel market expansion. Emerging markets, with improving healthcare infrastructure and rising cancer prevalence, also offer untapped growth potential.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.